Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
recombinant human Angiostatin protein · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| recombinant human Angiostatin protein | DRUG | - |
| paclitaxel | DRUG | - |
| carboplatin | DRUG | - |
Inclusion: * Histological or cytological confirmed Stage IIIB NSCLC with malignant pleural effusions, or Stage IV NSCLC or recurrent NSCLC * No previous chemotherapy for NSCLC * Have one lesion that is bidimensionally measurable by physical exam, MRI, or CT greater than 1 cm in diameter * Specified...
Recombinant human Angiostatin protein is being studied for the treatment of non-small-cell lung cancer, specifically carcinoma of the lung. It has been evaluated in a Phase 2 setting in combination with the chemotherapy agents paclitaxel and carboplatin in patients with this condition.
Recombinant human Angiostatin protein targets F9, also known as coagulation factor IX. It is classified as an exogenous protein therapeutic. By interacting with this target, the agent is designed to interfere with processes that support tumor growth and blood vessel formation in non-small-cell lung cancer.
Recombinant human Angiostatin protein is being developed by CASI Pharmaceuticals, Inc., which trades under the ticker symbol CASI. The company has sponsored clinical research for this agent in oncology, specifically in non-small-cell lung cancer.
Recombinant human Angiostatin protein is in Phase 2 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The Phase 2 trial evaluating it has been completed, and no active trials are currently listed.
Recombinant human Angiostatin protein has been studied in one completed clinical trial, NCT00049790, titled a safety and efficacy study of rhAngiostatin administered in combination with paclitaxel and carboplatin to patients with non-small-cell lung cancer. The trial was conducted in the United States and is no longer active.